MindMaze Therapeutics Holding SA (RLFTY)
OTCMKTS · Delayed Price · Currency is USD
1.410
-0.060 (-4.08%)
At close: Jan 26, 2026
RLFTY Revenue
MindMaze Therapeutics Holding had revenue of 1.22M CHF in the half year ending June 30, 2025, a decrease of -57.10%. This brings the company's revenue in the last twelve months to 4.05M, down -52.81% year-over-year. In the year 2024, MindMaze Therapeutics Holding had annual revenue of 8.42M with 39.52% growth.
Revenue (ttm)
4.05M CHF
Revenue Growth
-52.81%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
211.52M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.42M | 2.38M | 39.52% |
| Dec 31, 2023 | 6.03M | -48.00K | -0.79% |
| Dec 31, 2022 | 6.08M | 2.76M | 83.11% |
| Dec 31, 2021 | 3.32M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
MindMaze Therapeutics Holding News
- 2 months ago - Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics - Accesswire
- 2 months ago - Relief Therapeutics Publishes Joint Deck Ahead Of NeuroX Merger; Stock Up - Nasdaq
- 3 months ago - Relief Therapeutics Shareholders Approve Business Combination with NeuroX - Accesswire
- 3 months ago - Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 - Accesswire
- 6 months ago - Relief Therapeutics Publishes 2025 Half-Year Report - Accesswire
- 6 months ago - Relief Therapeutics Advances Publication of 2025 Half-Year Report - Accesswire
- 7 months ago - Relief Therapeutics reports proposed business combination with NeuroX - Seeking Alpha
- 7 months ago - Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze - Accesswire